Can ropinirole modulate reinforcing subjective effects of cocaine in humans?

Frontiers in Psychiatry

Volumn 2, Issue AUG, 2011, Pages

  Maremmani, Angelo Giovanni Icro ^a,b   Pacini, Matteo ^c   Rovai, Luca ^a   Rugani, Fabio ^a   Dell'Osso, Liliana ^a   Maremmani, Icro ^a,b,c  

^a UNIVERSITY OF PISA   (Italy)

^b Association for the Application of Neuroscientific Knowledge to Social Aims   (Italy)

^c G DE LISIO INSTITUTE OF BEHAVIOURAL SCIENCES   (Italy)

Author keywords

Anti craving effect; Blockade effect; Cocaine abuse; Ropinirole

Indexed keywords

COCAINE; DIAMORPHINE; ROPINIROLE;

ADULT; ARTICLE; BEHAVIOR CHANGE; CLINICAL ARTICLE; CLINICAL EVALUATION; COCAINE DEPENDENCE; COCAINE RUSH VISUAL ANALOG SCALE; DRUG DEPENDENCE TREATMENT; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; FEMALE; HEROIN DEPENDENCE; HUMAN; MALE; REINFORCEMENT; REWARD; SELF REPORT; VISUAL ANALOG SCALE;

EID: 84864997425     PISSN: None     EISSN: 16640640     Source Type: Journal    
DOI: 10.3389/fpsyt.2011.00050     Document Type: Article

References (39)

1. Barnett, P. G., Rodgers, J. H., and Bloch, D. A. (2001). A meta-analysis comparing buprenorphine to methadone for treatment of opiate dependence. Addiction 96, 683-690.
2. Bickel, W. K., Stitzer, M. L., Begelow, G. E., Liebson, I. A., Jasinski, D. R., and Johnson, R. E. (1988). Buprenorphine: dose-related blockade of opi-oid challenge in opioid dependent humans. J. Pharmacol Exp. Ther. 247, 47-53.
3. Budd, K. (1983). Buprenorphine. Clin. Anaesthesiol. 1, 139-179.
4. Caine, S. B., Negus, S. S., Mello, N. K., Patel, S., Bristow, L., Kulagowski, J., Vallone, D., Saiardi, A., and Borrelli, E. (2002). Role of dopamine D2-like receptors in cocaine self-administration: studies with D2 receptor mutant mice and novel D2 receptor antagonists. J. Neurosci. 22,2977-2988.
5. Cassano, G. B., Lattanzi, L., Litta, A., Lombardi, V., Tatulli, A., Benedetti, A., Longobardi, A., and Maremmani, I. (2009). Is aripripazole useful to refrain from cocaine use after detoxification (avoiding relapses)? Addict. Disord. Their Treat. 8, 161-166.
6. Castells, X., Casas, M., Perez-Mana, C., Roncero, C., Vidal, X., and Capella, D. (2010). Efficacy of psychostimulant drugs for cocaine dependence. Cochrane Database Syst. Rev. CD007380. doi: 10.1002/14651858.CD007380.pub3.
7. Collins, E. D., Vosburg, S. K., Hart, C. L., Haney, M., and Foltin, R. W. (2003). Amantadine does not modulate reinforcing, subjective, or cardiovascular effects of cocaine in humans. Pharmacol. Biochem. Behav. 76, 401-407.
8. Dackis, C. A., and O'Brien, C. P. (2001). Cocaine dependence: a disease of the brain's reward centers. J. Subst. Abuse Treat. 21,111-117.
9. de Lima, M. S., de Oliveira Soares, B. G., Reisser, A. A., and Farrell, M. (2002). Pharmacological treatment of cocaine dependence: a systematic review. Addiction 97, 931-949.
10. Dum, J. E., and Herz, A. (1981). In vivo receptor binding of the opiate partial agonist, buprenorphine, correlated with its agonistic and antagonistic actions. Br. J. Pharmacol. 74, 627-633.
11. George, T. P., Chawarski, M. C., Pakes, J., Carroll, K. M., Kosten, T. R., and Schottenfeld, R. S. (2000). Disul-firam versus placebo for cocaine dependence in buprenorphine-maintained subjects: a preliminary trial. Biol. Psychiatry 47, 1080-1086.
12. Grabowski, J., Rhoades, H., Silverman, P., Schmitz, J. M., Stotts, A., Creson, D., and Bailey, R. (2000). Risperi-done for the treatment of cocaine dependence: randomized, double-blind trial. J. Clin. Psychopharmacol. 20,305-310.
13. Haney, M., Rubin, E., and Foltin, R. W. (2011). Aripiprazole maintenance increases smoked cocaine self-administration in humans. Psychopharmacology (Berl.) 216, 379-387.
14. Hoefer, M. E., Voskanian, S. J., Koob, G. E, and Pulvirenti, L. (2006). Effects of terguride, ropinirole, and acetyl-L-carnitine on methamphetamine withdrawal in the rat. Pharmacol. Biochem. Behav. 83, 403-409.
15. Janiri, L., Martinotti, G., and Di Nicola, M. (2007). Aripiprazole for relapse prevention and craving in alcohol-dependent subjects: results from a pilot study. J. Clin. Psychopharmacol. 27,519-520.
16. Jost, W. H. (2004). Ropinirole: current status of the studies. J. Neurol. 251(Suppl. 6),VI/13-VI/18.
17. Kosten, T. R., George, T. P., and Kosten, T. A. (2002). The potential of dopamine agonists in drug addiction. Expert Opin. Investig. Drugs 11, 491-499.
18. Lam, Y. W. (2000). Clinical pharmacology of dopamine agonists. Pharma-cotherapy 20(1 pt 2), 17S-25S.
19. Maremmani, I., and Castrogiovanni, P. (1989). DAH-RS: Drug Addiction History Rating Scale. Pisa: University Press.
20. Maremmani, I., Pacini, M., Lubrano, S., Perugi, G., Tagliamonte, A., Pani, P. P., Gerra, G., and Shinderman, M. (2008). Long-term outcomes of treatment-resistant heroin addicts with and without DSM-IV axis I psychiatric comorbidity (dual diagnosis). Eur. Addict. Res. 14, 134-142.
21. Maremmani, I., Pani, P. P., Mellini, A., Pacini, M., Marini, G., Lovrecic, M., Perugi, G., and Shinderman, M. (2007). Alcohol and cocaine use and abuse among opioid addicts engaged in a methadone maintenance treatment program. J. Addict. Dis. 26, 61-70.
22. Martinotti, G., Di Nicola, M., Di Gian-nantonio, M., and Janiri, L. (2009). Aripiprazole in the treatment of patients with alcohol dependence: a double-blind, comparison trial vs. naltrexone. J. Psychopharmacol. 23, 123-129.
23. Matheson, A. J., and Spencer, C. M. (2000). Ropinirole: a review of its use in the management of Parkinson's disease. Drugs 60, 115-137.
24. McCance, E. E (1997). Overview of potential treatment medications for cocaine dependence. NIDA Res. Monogr. 175,36-72.
25. Meini, M., Capovani, B., Sbrana, A., Massei, G. J., Ravani, L., Mas-simetti, G., Daini, L., Scaramelli, D., and Moncini, M. (2008). A pilot open-label trial of ropinirole for cocaine dependence. Am. J. Addict. 17, 165-166.
26. Meini, M., Moncini, M., Cecconi, D., Cellesi, V., Biasci, L., Simoni, G., Ameglio, M., Pellegrini, M., For-gione, R. N., and Rucci, P. (2011). Aripiprazole and ropinirole treatment for cocaine dependence: evidence from a pilot study. Curr. Pharm. Des. 17,1376-1383.
27. Mutschler, J., Diehl, A., and Kiefer, E (2009). Pronounced paranoia as a result of cocaine-disulfiram interaction: case report and mode of action. J. Clin. Psychopharmacol. 29,99-101.
28. Ohuoha, D. C., Maxwell, J. A., Thomson, L. E. III, Cadet, J. L., and Rothman, R. B. (1997). Effect of dopamine receptor antagonists on cocaine subjective effects: a naturalistic case study. J. Subst. Abuse Treat. 14, 249-258.
29. Oliveto, A., Poling, J., Mancino, M. J., Feldman, Z., Cubells, J. F., Pruzinsky, R., Gonsai, K., Cargile, C., Sofuoglu, M., Chopra, M. P., Gonzalez-Haddad, G., Carroll, K. M., and Kosten, T. R. (2011). Randomized, double blind, placebo-controlled rial of disulfiram for the treatment of cocaine dependence in methadone-stabilized patients. Drug Alcohol Depend. 113,184-191.
30. Pani, P. P., Trogu, E., Vacca, R., Amato, L., Vecchi, S., and Davoli, M. (2010). Disulfiram for the treatment of cocaine dependence. Cochrane Database Syst. Rev. 1, CD007024.
31. Perugi, G., Toni, C., Ruffolo, G., Frare, E, and Akiskal, H. (2001). Adjunc-tive dopamine agonists in treatment-resistant bipolar II depression: an open case series. Pharmacopsychia-try 34, 137-141.
32. Petrakis, I. L., Carroll, K. M., Nich, C., Gordon, L. T., McCance-Katz, E. F., Frankforter, T., and Rounsaville, B. J. (2000). Disulfiram treatment for cocaine dependence in methadone-maintained opioid addicts. Addiction 95,219-228.
33. Rawson, R. A., Obert, J. L., McCann, D. P., Smith, D. P., and Scheffey, E. H. (1989). The Neurobehavioural Treatment Manual: A Therapist Manual for Outpatient Cocaine Addiction Treatment. Bevery Hills, CA: Matrix Center.
34. Soares, B. G., Lima, M. S., Reisser, A. A., and Farrell, M. (2003). Dopamine agonists for cocaine dependence. Cochrane Database Syst. Rev. CD003352. doi: 10.1002/14651858.CD003352.pub2.
35. Sofuoglu, M., and Kosten, T. R. (2005). Novel approaches to the treatment of cocaine addiction. CNS Drugs 19, 13-25.
36. Tulloch, I. E (1997). Pharmacologic profile of ropinirole: a nonergoline dopamine agonist. Neurology 49(1 Suppl. 1),S58-S62.
37. Virk, M. S., Arttamangkul, S., Birdsong, W. T., and Williams, J. T. (2009). Buprenorphine is a weak partial agonist that inhibits opioid receptor desensitization. J. Neurosci. 29, 7341-7348.
38. Walsh, S. L., Preston, K. L., Bigelow, G. E., and Stitzer, M. L. (1995). Acute administration of buprenorphine in humans: partial agonist and blockade effects. J. Pharmacol. Exp. Ther. 274, 361-372.
39. Zuurmond, W. W., Meert, T. F., and Noorduin, H. (2002). Partial versus full agonists for opioid-mediated analgesia-focus on fentanyl and buprenorphine. Acta Anaesthesiol. Belg. 53,193-201.